Pharmaceutical packaging artwork passes through more hands than almost any other document in a regulated organization — regulatory affairs, quality assurance, the artwork studio, marketing, medical and legal review, sometimes an external agency. It moves through multiple revision cycles, in multiple languages, before it is ready for print. At any handoff, a change can be made, a version confused, or a check skipped — and in pharma, the consequence isn't a rejected proof. It's a released product with an error on the label.
This guide covers what a pharma artwork approval process actually involves, the specific points where errors most consistently enter the process, what GxP compliance requires of that process, and how to structure a workflow that produces a defensible, audit-ready result — regardless of which software or systems are involved.
Scope note: this guide covers the artwork approval process specifically — the workflow between approved regulatory text and a signed-off, print-ready file. It does not cover the regulatory submission process that produces the approved text, or the selection of artwork management or PLM systems.
What Pharma Artwork Approval Actually Involves
Artwork approval in pharma is distinct from two things it's often confused with. It is not the regulatory submission process — that process produces the approved Summary of Product Characteristics, Package Leaflet, or prescribing information, which becomes the source content for the label. And it is not artwork management, which refers to the systems that store, route, and version-control artwork files. Artwork approval sits between the two: it is the process of verifying that the artwork about to be printed or released accurately reflects the regulatory text that was approved, in every language, on every packaging component, with every intended change captured and every unintended change caught.
The stakeholders typically involved are Regulatory Affairs, which owns the approved source text; Quality Assurance, which owns the final release decision; the artwork studio or a design agency, which produces the physical layout; and often Marketing or Medical/Legal, particularly where branding or promotional claims intersect with the packaging. A single SKU sold across multiple markets can generate a large number of language and market variants, each requiring the same verification discipline.
The process exists in its current, often heavily documented form because of specific regulatory expectations: 21 CFR Part 11 requires that electronic records used in a GxP process — including artwork approval records — carry a defensible audit trail, and EU GMP requires a documented, controlled change process for anything affecting a marketed product's labeling. The rigor isn't bureaucratic overhead; it exists because an error that reaches a patient is categorically different from an error that reaches a customer in almost any other industry.
The Five Points Where Pharma Artwork Errors Enter the Process
Documented FDA recall patterns and GxP inspection findings point to a consistent set of entry points for artwork errors — not because teams are careless, but because these are the specific junctures where a systematic check is most likely to be replaced by a manual one, or skipped.
The late revision. A change requested after the artwork has already completed its formal review cycle — a dosage clarification from Regulatory, a corrected storage condition, a legal wording adjustment — is applied directly to the near-final file. Whether that change gets the same level of scrutiny as the original review depends entirely on whether the process treats late changes as requiring a full re-review, or as a quick, informal edit.
The wrong version. An approval is recorded against a specific file, but by the time that file reaches production, a different version — with an intervening change — has taken its place. The approval record shows sign-off happened; it doesn't confirm that what was approved is what shipped.
The unpropagated change. A correction made to the master content — in one language, on one market's artwork — needs to be reflected identically across every other language and market variant of the same product. When each variant is reviewed independently rather than checked against the others, an update applied in the source language can fail to reach a translated version, and nothing in a single-language review catches the gap.
The format conversion error. Moving artwork between file formats — a PDF export, a conversion between design and pre-press software — can introduce changes invisible on screen: text flattened into a non-editable image, a character encoding shift that alters how a Unicode character is stored, a hidden or non-printing layer that persists from an earlier draft. None of these are visible to a reviewer looking at a rendered page.
The manual final comparison. The last check before a file is released for print is, in many processes, a visual read — someone comparing the final artwork against the previous version, or against their memory of what should be there. Manual review under time pressure, at the end of a long approval cycle, is a documented point of failure precisely because attention and time pressure work against each other at exactly the moment the check matters most.
What GxP Compliance Requires of the Artwork Approval Process
For any organization using electronic systems in the artwork approval process — which is effectively every pharmaceutical company today — 21 CFR Part 11 and EU GMP Annex 11 set specific requirements that the process, and the systems supporting it, must meet.
Audit trail. The system must generate a secure, computer-generated, time-stamped record documenting who took an action, what the action was, what changed, and when. A system that logs that someone accessed a file, but not what they changed or what the previous value was, does not meet this requirement — a common and specific point of failure identified in FDA inspection findings.
Electronic signatures. Signatures applied within the system must be unique to the individual, non-reusable, and linked to the specific record in a way that prevents the signature being separated from what was actually approved. A shared login or a signature tied to a role rather than a specific person does not meet this bar.
System validation. Any computerized system used to make or support a decision affecting a GxP record — including a comparison or proofreading tool used to verify artwork before release — falls within the scope of validation requirements. This means the tool itself needs Installation Qualification, Operational Qualification, and Performance Qualification (IQ/OQ/PQ) documentation, proportionate to its role in the process.
The practical implication is that "our review process is thorough" is not, on its own, a sufficient answer to a regulatory inspector. The process needs to produce evidence — an audit trail, signed approvals tied to specific document versions, and validated tooling — that the review actually happened, on the actual released version, by the actual named individuals.
Designing a Compliant Pharma Artwork Approval Workflow
A defensible artwork approval workflow follows a consistent structure, regardless of the specific software involved:
1. Approved regulatory text locked as the master. The SmPC, PIL, or prescribing information approved by the relevant regulatory authority becomes the fixed source of truth. Every subsequent artwork version is measured against this master, not against the previous draft.
2. Artwork creation against the master. The studio or design team produces the layout, incorporating the approved text, required symbols, Braille, and barcodes. This step is outside the scope of a verification tool — it's the creative and technical production of the file.
3. Text comparison against the approved master, every language. Every language version of the artwork is compared character by character against the master content, not against the previous version of that language's artwork. This is the step that catches unpropagated changes and late-revision errors.
4. Graphic comparison for layout and visual accuracy. Pixel-level comparison confirms logo placement, image content, color accuracy, and layout integrity — catching visual changes that text comparison cannot detect.
5. Braille and barcode verification, in the same pass. Rather than treating Braille and barcode as separate checks run by a different tool or team, verifying them within the same session as text and graphics closes the handoff gap where these elements are most often checked last, and least reliably.
6. Version-controlled sign-off. Approval is recorded against a specific, identifiable document state — ideally a file hash or equivalent unique identifier — not a file name that could apply to more than one version over time.
7. QA release on a single structured report. Rather than assembling separate outputs from separate comparison tools, QA reviews and signs off on one report covering every comparison type that was run.
8. Audit trail generation. Every step — who ran the comparison, what was compared, what deviations were found, how they were resolved, who signed off — is captured automatically and remains available without reconstruction, ready for an inspection at any point afterward.
This structure works whether the comparison steps are performed with a single integrated platform or with multiple separate tools — though the operational cost, validation burden, and risk of gaps between tools differ significantly between those two approaches.
Common Gaps in Pharma Artwork Approval Processes — and Why They Persist
Several structural reasons explain why gaps persist in pharma artwork approval processes even at organizations with genuinely rigorous quality cultures.
Legacy systems built before current GxP expectations. Many artwork review workflows were established before current audit trail and electronic signature expectations were fully articulated, and have been patched incrementally rather than redesigned.
Siloed tools for different comparison types. Where text comparison, graphic comparison, barcode grading, and Braille verification each require a separate application, the review process inherits every gap between those tools — different validation status, different reporting formats, and a manual assembly step to bring the results together before sign-off.
Email-based routing without version control. Particularly for smaller markets or lower-volume products, informal routing via email remains common. This makes it structurally difficult to guarantee that every reviewer saw the same version, or that the version ultimately approved is the version that reaches production.
Sign-off that records approval, not document state. A signature confirms someone approved "the artwork" — but if that approval isn't tied to a specific, unambiguous version identifier, it doesn't confirm which artwork, at which point in its revision history, was actually reviewed.
None of these gaps reflect a lack of diligence. They reflect a process that has accumulated complexity over time without a corresponding investment in the verification layer that would catch what the complexity creates.
How Artwork Approval Interacts With Artwork Management and Regulatory Systems
Artwork approval doesn't operate in isolation — it sits within a broader ecosystem of systems that most pharmaceutical companies already have in place. Artwork management systems (AMS) and PLM platforms handle file storage, routing, and workflow orchestration. Regulatory submission systems manage the eCTD and SPL content that constitutes the approved source text. Systems like Veeva Vault often serve as the system of record for regulatory content across an organization.
A verification layer operates at a specific point within this ecosystem: it receives the artwork file, whatever system produced or routed it, and compares it against the approved master. It doesn't replace the artwork management system's storage and workflow functions, and it doesn't replace the regulatory system that produced the approved text — it confirms that what's about to be released accurately reflects what was approved, and it connects into the broader ecosystem through standard file-based or API-based integration with the tools already in place.
A compliant artwork approval process isn't defined by the absence of errors — even the most rigorous manual process will occasionally miss something, because human attention has limits that don't scale with document complexity or deadline pressure. It's defined by having a systematic, documented, defensible check at the point where the file becomes final — one that catches what manual review reliably misses, and that produces the evidence an inspection will ask for.
Content Compare runs that check: text, graphic, Braille, and barcode verification against the approved master, in a single validated session, with the audit trail built into every comparison.
See what a compliant artwork approval workflow looks like on your own documents. Request a demo.
